Clinical guideline
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Ann Oncol · 2026
Evidence library
Structured summaries of the key trials and international clinical guidelines that underpin today’s cancer treatments.
659 studies129 guidelines21 areas
Browse by cancer type
Breast cancer91 studies · 7 guidelinesColorectal cancer54 studies · 11 guidelinesStomach cancer28 studies · 4 guidelinesLung cancer44 studies · 5 guidelinesProstate cancer39 studies · 4 guidelinesBlood cancers54 studies · 12 guidelinesBladder cancer21 studies · 2 guidelinesLeukaemia17 studies · 1 guidelineOesophageal cancer17 studies · 3 guidelinesThyroid cancer13 studies · 7 guidelinesBrain tumours17 studies · 5 guidelinesHead and neck cancers25 studies · 2 guidelinesLiver cancer19 studies · 7 guidelinesPancreatic cancer23 studies · 6 guidelinesLymphoma28 studies · 4 guidelinesMultiple myeloma16 studies · 4 guidelinesKidney cancer23 studies · 6 guidelinesOvarian cancer23 studies · 2 guidelinesCervical cancer21 studies · 6 guidelinesMelanoma24 studies · 4 guidelinesOther areas and general studies49 studies · 40 guidelines
International clinical guidelines
Key recommendations of ESMO, NCCN, EAU and other societies.
Clinical guideline
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
J Hepatol · 2026
Clinical guideline
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
J Natl Compr Canc Netw · 2026
Clinical guideline
EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update
Eur Urol · 2026
Clinical guideline
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
Eur Urol · 2026
Clinical guideline
EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation
HemaSphere · 2026
Latest studies
Clinical trial · Phase 3
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Lancet · 2026
HR 0.72Radiographic progression-free survival
Clinical trial · Phase 3
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
Lancet · 2026
82% vs 81%4-year FFS: A+I vs I
Clinical trial · Phase 3
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
Annals of Oncology · 2026
21.9 months (95% CI 18.8–36.9) with nivolumab vs 11.0 months (8.3–16.6) with placeboMedian DFS in all randomised patients
Clinical trial · Phase 3
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study
Ann Oncol · 2026
60.9% vs 52.2%5-year disease-free survival
Clinical trial · Phase 3
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
N Engl J Med · 2026
80.7% vs 73.7%24-month disease-free survival
Review article
Advances in multiple myeloma: key updates from the ASH 2025 meeting
J Hematol Oncol · 2026
Conversion from persistent MRD-positive to MRD-negative in all evaluable patientsIMMUNOPLANT (MRD-adapted consolidation in NDMM)